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Bipolar disorder (BD) is a chronic and often severe psychiatric illness characterized by manic and depressive episodes. Among the
most eﬀective treatments, mood stabilizers represent the keystone in acute mania, depression, and maintenance treatment of BD.
However, treatment response is a highly heterogeneous trait, thus emphasizing the need for a structured informational framework
of phenotypic and genetic predictors. In this paper, we present the current state of pharmacogenomic research on long-term
treatment in BD, speciﬁcally focusing on mood stabilizers. While the results provided so far support the key role of genetic factors
in modulating the response phenotype, strong evidence for genetic predictors is still lacking. In order to facilitate implementation
of pharmacogenomics into clinical settings (i.e., the creation of personalized therapy), further research eﬀorts are needed.
1.Introduction
Bipolar disorder (BD) is a clinically severe psychiatric
disorder, characterized by recurrent alternating episodes of
mania and depression, with a lifetime prevalence of 0.7%–
6% [1–3].
Given its high morbidity, disability, and premature
mortality [4], BD is a major health problem with severe
socioeconomic implications. The economic burden of BD
has been estimated at $45 billion per year in the United
States in 1991, with a total of $7 billion of direct costs
consisting of expenditures for inpatient and outpatient care
[5, 6]. A very recent report analyzing the inpatient care
costs for bipolar I disorder in Europe demonstrated that
huge resources and frequent hospitalizations are required,
especially in managing manic episodes [7]. Moreover, it has
been shown that BD has a signiﬁcant negative eﬀect on
work relationships, attendance, and functioning, with an
overall increase in costs deriving from lost productivity [8].
Family, twin and adoption studies have demonstrated that
BD is characterized by a high heritability, suggesting that
genes exert a high-magnitude eﬀect on disease development
[9, 10]. In light of this evidence, great eﬀort has been made
to identify the genetic factors involved in the pathogenesis
of BD, although fulﬁlling results have not yet been obtained.
Investigations carried out to date on a genome-wide level
using case-control study designs have thrown light on two
genes, the ankirin G (ANK3) and the alpha 1C subunit of the
L-type voltage-gated calcium channel (CACNA1C) [11].
Consequently, a number of studies have further inves-
tigated the role of these genes in BD. In regard to ANK3,
its association has been displayed ex novo or replicated in
several other studies, although with diﬀerent eﬀect size and
association magnitude for the polymorphisms analyzed [12–
16].FollowingtheﬁrstreportofitsassociationwithBD[17],
CACNA1C has been further investigated in some studies. In
2008, using the Wellcome Trust Case-Control Consortium
datasetascomparison[18],agenome-wideassociationstudy
(GWAS) of BD identiﬁed concordant association signals in
the CACNA1C gene, although the genome-wide signiﬁcance
wasnotreached[13].Sincethenandupholdingthereportby
Ferreira et al. [11], the possible causative role of CACNA1C2 Human Genomics and Proteomics
in BD has been conﬁrmed by gene-wide analysis [19],
although further evidence is needed to assess its eﬀects on
the disease [20]. Very recently, a meta-analysis of genome
wide association data on major mood disorders, including
BD, has identiﬁed a risk locus on 3p21.1 with the most sig-
niﬁcant association signal located in the protein polybromo-
1 (PBRM1) and guanine nucleotide binding protein-like 3
(GNL3) genes, whose encoded products are, respectively,
involved in chromatin remodelling and the proliferation of
stemcells[21].AmongthegenespossiblycontributingtoBD
susceptibiliy the diacylglycerol kinase eta (DGKH), encoding
for an enzyme that phosphorylates the second messenger
diacylglycerol, was ﬁrst found to be associated with BD in
the GWAS by Baum et al. [12], although replication was not
uniformly displayed by subsequent studies [22–24].
On the whole, this evidence seems to indicate that
the biological underpinnings of BD appear to be highly
heterogeneous on the genetic and molecular level. Moreover,
it is unlikely that common variants of large eﬀect-size are
causative of BD, if, for instance, meta-analysis of GWAS data
in BD displayed relatively low odds ratios (OR) of 1.45 and
1.18 and minor allele frequencies (MAF) in cases of 0.07 and
0.38 for ANK3 and CACNA1A genes, respectively [11].
This highly heterogeneous genetic framework character-
izing BD reﬂects on the broad variability of its phenotypic
expression, with clinical symptoms presenting diﬀerent pat-
terns within subjects (longitudinal variability) and between
subjects [25–27].
The genetic and phenotypic heterogeneity of BD clearly
plays a pivotal role in pacing the way to the discovery of
biological determinants of the disease. Speciﬁcally, indis-
putable associations between the genetic variants identiﬁed
to date and the phenotypic changes manifested in BD
are still lacking. In this context, an appropriate phenotype
deﬁnition represents a powerful tool in the search for
susceptibility genes in BD [27, 28]. To this end, several
subphenotypes have been studied to reﬁne the phenotype
and consequently increase the possibility of detecting genetic
determinants [27, 29] .T h er e s p o n s et ol o n g - t e r mt r e a t m e n t
with mood stabilizers has been suggested to be a clinical trait
suitable for identifying distinct subgroups of BD with greater
homogeneity and for the mapping of genes involved in the
biological basis of treatment response and in the disorder
itself [27, 30, 31].
On the one hand, the reduction of heterogeneity might
depend on the identiﬁcation of common phenotypic pat-
terns in the clinical presentation of the disease [27]. On
the other hand, the narrower are the criteria for the
deﬁnition of treatment response, the greater the probability
of reducing genetic heterogeneity and consequently of
detecting causative determinants of diﬀerences in response
to medications.
Phenotypic assessment is the harbinger of more complex
research strategies such as pharmacogenomics, which aim
to assemble the molecular and phenotypic heterogeneity
jigsaw puzzle in the study of treatment response. Indeed,
pharmacogenomicsisthegenome-wideanalysisoftheroleof
genetic determinants in modulating an individual’s response
to a drug treatment or the onset of adverse drug reactions
(ADRs). Along with its use as a strategy for reducing
heterogeneity and consequently for shedding light on the
biological underpinnings of the disease, the integration of
pharmacogenomic data with speciﬁc individual phenotypic
information, represents a powerful instrument for the devel-
opment of personalized therapies.
Although the data collected by numerous studies have
not yet reached a suﬃcient magnitude to signiﬁcantly
impact the clinical ﬁeld, pharmacogenomics in BD is a
rapid-evolving research ﬁeld. Speciﬁcally, most of the phar-
macogenomic studies performed in BD have focused on
candidate genes selected according to the biological rationale
supporting their involvement in the drugs’ mechanism of
action, in the biological basis of the disease and in the
metabolic pathways implicated in the onset of ADRs.
In this paper, we present the current state of the
pharmacogenomic research on long-term treatments in BD,
speciﬁcally focusing on mood stabilizers. In the introductory
section, we discuss the issues pertaining to the currently-
available mood stabilizing treatments for BD, the appro-
priate deﬁnition of the treatment response phenotype and
its implication for pharmacogenomics studies. Then we
selectively review existing evidence on genetic predictors of
maintenance treatment response in BD, ﬁrstly presenting
an overview of the molecular targets involved in mood
stabilizers mechanism of action and then focusing on
presently available reports on the genetic determinants of
treatment response.
2. Pharmacogenomics in Bipolar Disorder:
PhenotypicFeaturesandHeritability
Patterns of Long-Term Treatment Response
2.1. Long-Term Treatments in Bipolar Disorder: Lithium,
Anticonvulsants,andAntipsychotics. Itiswidelyacceptedthat
the term “mood stabilizers”, although not yet uniformly
validated, may be applied to several classes of drugs, such
as anticonvulsants, antipsychotics (particularly the second
generation antipsychotics or atypical), and lithium which,
although diﬀerent in terms of mechanism of action and
chemical structure, commonly act as prophylactic agents
able to prevent illness recurrences. Ideally, a mood stabilizer
should be eﬃcacious in: (1) treatment of acute manic
symptoms, (2) treatment of acute depressive symptoms,
(3) prevention of manic symptoms, and (4) prevention
of depressive symptoms [32]. Among the mood stabilizing
agents, lithium, more than the others, seems to meet these
criteria, further strengthening the rationale for its use as
ﬁrst-line treatment in BD [32–35]. In this regard, numerous
controlled and open trials have clearly shown that lithium
is able to reduce the frequency of episode recurrences by at
least 30% [33, 35]. A randomised open-label trial recently
demonstrated that both combination therapy with lithium
plus valproate (VPA) and lithium monotherapy are more
likely to prevent relapse than is valproate monotherapy
[36]. Therefore, it is not surprising that since its ﬁrst
introduction in the clinical use in 1949 by Cade [37], lithium
has remained one of the mainstays in the treatment ofHuman Genomics and Proteomics 3
BD, a practice further corroborated by its high eﬃcacy in
reducingsuicidalityinpatientswithrecurrentmajoraﬀective
disorders [38, 39].
Along with lithium, anticonvulsants and antipsychotics,
represent valid alternatives for the therapeutic manage-
ment of BD. Among anticonvulsants, three drugs [VPA,
lamotrigine (LTG) and carbamazepine (CBZ)] have strong
evidence-based support for use in clinical states of BD [40,
41]. Speciﬁcally, VPA, LTG and CBZ have data supporting
their roles as potential long-term treatments to prevent
relapse [40, 41]. LTG has a greater eﬀect on the prevention
of depression while has lacked eﬃcacy in mania or in
acute bipolar depression [41]. On the other hand, VPA
is eﬀective in the treatment of mania, somewhat more
eﬀective in certain patient subgroups (mixed mania, mania
with prominent irritability) than other treatments; recent
proof-of-concept indicates beneﬁts in bipolar depression,
while there is clear evidence that CBZ is eﬀective in
treating mania [41, 42]. Among the other anticonvulsants,
gabapentin (GBP) and topiramate (TPM) have not been
shown to be superior to placebo in randomized trials,
although GBP might be useful in controlling anxiety in BD
[41].
Antipsychotics, and speciﬁcally the class of atypical,
appear to be eﬀective in the treatment of mania, although
their potential in the long-term management of BD is
still subject of debate [43, 44]. A systematic review of
randomized trials for treatment of the maintenance phase in
BD supported evidence that, along with lithium, LTG and
VPA, olanzapine is eﬀective in long-term use signiﬁcantly
reducing manic relapses [45].
Although this evidence describes a background of multi-
ple therapeutic tools available for the treatment of BD, a rela-
tivelyhighpercentageofpatientsstillpresentlackofresponse
evenafterconsecutivetrialsofdiﬀerentdrugs.Inthiscontext,
it appears crucial to develop theoretical frameworks useful
in identifying clinical predictors of response by categorizing
BD patients according to diﬀerent diagnostic spectra. In this
regard, a three-spectrum model of BD has been proposed,
describing diﬀerent subtypes of BD (classical, psychotic and
characterological) characterized by speciﬁc clinical features
and more importantly by speciﬁc patterns of drug treatment
response [25]. This model supports the importance of the
carefuldiagnosticassessmentofBDatthephenomenological
level, as some speciﬁc clinical features, such as family history,
clinical course and comorbidity are strictly linked to the
treatment response phenotype.
2.2. The Phenotype First. Deﬁnition of the treatment
response phenotype is a crucial process propaedeutic to any
subsequentpharmacogenetic/genomic analysisthe value and
reliability of the latter based on an accurate assessment of
the former. Diagnoses are expected to be heterogeneous in
BD, and similarly, quantiﬁcation of the treatment response
in clinical terms, a complex trait in itself, may vary. In
detail, evaluation of treatment response outcomes has for
the most part been performed considering it a binary-trait
(0 = unaﬀected/nonresponders, 1 = aﬀected/responders).
However,ithasbeensuggestedthat,sincetreatmentresponse
is a quantitative trait, this approach might not totally
represent the complex nature of this phenotype. Indeed,
deeming treatment response a quantitative trait can facilitate
theidentiﬁcationofgeneticvariantsinvolvedinintermediate
phenotypes, as for instance partial response to a drug. It is
important to note that the binary-trait approach does not
take into account the degree of variation in the treatment
response phenotype, which can be represented as a gradient
lying within the two extremes of complete nonresponse
and complete response. On the other hand, comparing and
contrasting the genetic diﬀerences at the two extreme points
of the gradient (extreme discordant phenotype (EDP)) can
increase the statistical power and consequently the probabil-
ity of detecting the causative variants for the response or lack
of response to a drug [46, 47].
In BD, eﬀorts thus far to develop a stringent deﬁnition of
treatment response, especially in long-term therapies, have
applied analytical tools such as the Aﬀective Morbidity Index
(AMI) [48, 49] and the illness severity index [50]. Brieﬂy,
these approaches take into consideration the severity and
the duration of episodes before and after the introduction of
the mood stabilizing therapy, allowing quantiﬁcation of the
degree of improvement under a speciﬁc treatment. However,
these approaches do not take into account the presence
of possible confounders (such as additional medication or
lack of compliance) that may interfere in the establishment
of a causal relationship between the clinical improvement
and the treatment. In this regard, in 2002 Grof et al.
[51] developed a rating scale that measures the degree of
improvement in the course of treatment and weighs clinical
factors considered relevant for determining whether or not
the observed improvement is due to the treatment. This scale
allows enucleating the full response phenotype, meaning
the absence of abnormal mood episodes during treatment.
Moreover, since the scale consists of eleven items (0–
10), it also permits identiﬁcation of intermediate response
phenotypes (i.e., partial response) and the EDP approach,
both aspects supporting its validity for the implementation
in pharmacogenomic studies of treatment response.
In general, the assessment of treatment response phe-
notype in BD shows quite similar rates of reduction of
illness recurrence among the diﬀerent mood stabilizing
therapies. In regard to lithium, clinical data show that
∼80% of chronically-treated subjects are at least partial
responders and that ∼30% of these patients are excellent
responders with a complete remission of symptoms [52].
In a review of 20 randomized, double-blind controlled
studies of monotherapy or combination therapy for the
treatment of acute mania, the pooled response rates of 15
monotherapy studies were around 50% for lithium, VPA,
CBZ or atypical antipsychotics (21% greater than placebo),
while the remaining 5 combination studies showed an
incremental beneﬁt of adding a second agent equal to 21%
[53].
However, treatment refractoriness in BD still remains a
challenge [54], further encouraging the search for response
predictors that might allow identiﬁcation of the most
eﬀective treatment for carriers of speciﬁc genetic-variation
patterns.4 Human Genomics and Proteomics
2.3. The Phenotypic Features and Heritability Patterns of
Long-Term Treatment Response. In light of the complexity
of the drug response phenotype, the pharmacogenomic
approach might beneﬁt from analysis of convergent ﬁndings
on prediction of treatment response on the phenotypic and
genetic level. It has been suggested that pharmacogenomic
studies should consider nongenetic factors that can interact
in inﬂuencing the phenotype [55]. Genetic work can be
informed and guided by appropriate clinical details and
can allow investigation of possible genotype-phenotype
information. In BD, this joint analytical approach has led
to intriguing ﬁndings on signiﬁcant interactions between
lithium treatment response, gene variation and speciﬁc
clinical features [56].
Since clinical markers of treatment response can have
predictive power that may allow the targeting of therapies to
subpopulation of patients characterized by speciﬁc pheno-
typic traits, it is important to establish their correlation with
treatment response outcome. In this context, a large amount
of evidence has been gathered over the years on outcome
predictorsforlong-termtreatmentswithCBZ,VPA,LTGand
lithium [57–59].
Treatment response to CBZ seems to be predicted by
clinical features such as mood-incongruent psychosis, lack of
responseorintolerancetolithium,whilecontrastingﬁndings
are present on the possible predictive value of rapid cycling,
severe mania and dysphoric mania [25, 57, 60]. Responders
to VPA are characterized by the presence of pure, mixed
or dysphoric mania. Moreover, early age at onset, rapid-
cycling, concurrent substance abuse and lack of response
or intolerance to lithium are clinical markers of positive
outcome with VPA [57]. Response to LTG seems to be
predicted by earlier onset of symptoms, non episodic course
of illness, rapid cycling, comorbidity with panic or substance
use disorder, fewer hospitalizations, fewer prior medication
trials and male gender [61, 62].
Responders to lithium are a group of patients with
distinct clinical features corresponding to the bipolar dis-
order core phenotype [33, 63]. An episodic pattern of
mania-depressioninterval,lowratesofcomorbidconditions,
absence of rapid cycling and high age at illness onset have
been identiﬁed as potentially protective against a recurrence
under lithium [59, 64–66].
In addition, family history might also provide impor-
tant insights on the prediction of treatment outcome. For
instance, relatives of LTG responders present a greater
prevalenceofschizoaﬀectivedisorders,majordepressionand
panic attacks, while lithium responders had a higher risk of
BD [59]. In this regard, it is important to note that since the
ﬁrst report by Mendlewicz et al. [67], which pointed out a
signiﬁcant correlation between response to lithium and the
presence of BD in the proband’s ﬁrst degree relatives, this
ﬁnding has been conﬁrmed over a period of more than thirty
years [50, 62, 68–74]. Moreover, Grof et al. [51] showed
that lithium response in itself clusters in families. Analyzing
the genetic patterns of heritability, Alda et al. [75, 76]
suggested that a recessive model with sex-speciﬁc penetrance
could explain the mode of inheritance in BD responsive to
lithium.
On the whole, these ﬁndings clearly show that treat-
ment response is a heritable clinical feature, evidence that
corroborates the rationale for pharmacogenomic approaches
in BD. Moreover, they underscore the importance of an
accurate collection of clinical data which, if analyzed jointly
with genetic information, could lead to precise prediction of
treatment outcome in BD patients.
3.MolecularMechanisms ofMoodStabilizers
Considerable evidence has shown that BD is characterized
by neurotrophic alterations resulting in impairment of
signalling and neuroplasticity with a signiﬁcant overall
reduction in central nervous system (CNS) volume (for a
review, see [77]). Neuroimaging studies have demonstrated
that BD and major depressive disorder (MDD) patients have
several brain volumetric alterations such as enlargement of
ventricles, reduced grey matter volumes in the orbital and
medial prefrontal cortex (PFC) and reduced volumes in
the frontal lobe and hippocampus [78–82]. Post-mortem
studies have also shown that the reduced volumes of PFC
and orbitofrontal cortices are associated with decreased
neuron numbers and/or size [83, 84]. Other studies reported
reductions in the number of interneurons in the anterior
cingulated cortex of BD patients as compared to controls
as well as reductions in nonpyramidal neurons in the
hippocampus [85, 86].
It has been shown that the clinical eﬃcacy of lithium
correlates with measurable changes in the CNS of treated
subjects, who displayed increased volumes in speciﬁc brain
areas after chronic treatment. Recently, a longitudinal study
conducted from 1997 until 2004 evaluated the eﬀect of
lithium on grey matter volumes of diﬀerent brain areas of 28
bipolar subjects with diﬀerent response to lithium medica-
tion, using morphometric magnetic resonance imaging [87].
A signiﬁcant increase in total brain grey matter volume was
identiﬁed after chronic lithium administration. Interestingly,
the regional analysis showed that the grey matter volume of
PFC was signiﬁcantly increased only in lithium responsive
BDsubjects.Thesedatashowthattheeﬀectoflithiumonthe
CNS has clinical consequences and corroborate the evidence
on its neurotrophic eﬀect. Nevertheless, the mechanism by
which lithium increases grey matter volumes is still under
investigation.
A large body of evidence shows that lithium interacts
with many elements of second messenger systems thus mod-
ulating processes both up- and downstream of its targets.
Lithium competes with magnesium for a large number of
enzymesrequiringitasacofactor[88,89].Earlyreportsshow
that lithium directly inhibits two enzymes of the inositol
pathway, the inositol monophosphate phosphatase (IMPase)
and the inositol polyphosphate 1 phosphatase (IPPase), at
therapeutic serum concentration (0.6–1.2mM) [90]. This
evidence led to the inositol depletion hypothesis of lithium’s
mechanism of action, which would exert its mood stabilizing
eﬀects by decreasing inositol levels, thus ultimately inﬂuenc-
ing a number of processes relying on this pathway, including
neurotrophin and G protein mediated signalling [91]. ThisHuman Genomics and Proteomics 5
hypothesis is also supported by ﬁndings from animal studies
[92–94].
Like lithium, VPA has been shown to have neuropro-
tective eﬀects. It has been reported that VPA interacts with
the inositol pathway, but through a diﬀerent mechanism
compared to lithium. VPA does not directly inhibit IMPase,
and the inositol depletion is mediated by a decrease in
inositol phosphates and inositol levels [95, 96].
A number of ﬁndings have also shown that lithium
and VPA interact with the activator protein 1 (AP-1), a
family of transcription factors composed of heterodimeric
complexes of c-Jun and c-Fos proteins. Lithium has been
shown to increase AP-1 binding activity and transcription in
cultured cells [97, 98]. Other studies have reported that VPA
increases AP-1 DNA binding and activation in cultured cells
[99, 100]. However, while lithium regulates AP-1 through
the inhibition of glycogen synthase kinase 3β (GSK-3β),
VPA induces the expression of c-Jun and c-Fos by means of
histone deacetylase (HDAC).
GSK-3β is a highly-conserved protein involved in the
regulation of apoptosis, circadian rhythm and a wide range
of neuronal functions and pathways involved in cell and
tissue development (for a review, see [101]). A large number
of processes and pathways converge on GSK-3β including
theWingless-INT(Wnt)signalling,severalneurotransmitter
pathways, and Akt, with the latter shown to inhibit GSK-3β
in response to multiple hormones and neurotrophic factors,
including the brain derived neurotrophic factor (BDNF)
[102].
Lithium,likeVPA,inhibitsGSK-3β activityinmouseand
rat brain at therapeutically relevant doses [103–105]. It has
been reported that lithium inhibition of GSK-3β is mediated
through competition for magnesium, an essential cofactor
for GSK-3β, while VPA inhibition is indirect [89, 106, 107].
The inhibitory eﬀect of lithium and VPA on GSK-3β may
represent one of the key mechanisms through which they
regulate neuronal plasticity and neurogenesis. In this regard,
it has been shown thatalternative inhibitors of GSK-3β aﬀect
neurogenesisinembryonicstemcells[108–110]andstabilize
g r o w t hc o n e si nc u l t u r e ds e n s o r yn e u r o n s[ 111]. Along with
lithium, VPA and CBZ were shown to inhibit the collapse of
sensory neuron growth cones and to increase growth cone
area [112].
It has been shown that the serotonergic pathway is a
downstream target of GSK-3β [113]. This evidence led to
the hypothesis of an involvement of GSK-3β in depression
and might explain the eﬀectiveness of lithium as an add-
on in the treatment of antidepressant-refractory depression
[114, 115]. In this regard, a recent ﬁnding showed that
lithium decrease serotonin release in primary serotonergic
neurons from rat raphe nuclei [116]. In the same study,
the authors reported that short-term lithium treatment (8
days) resulted in a 45% decrease in tryptophan hydroxylase
2 (TPH2) expression and a 31% reduction in TPH2 protein
levels, completely compensated after long-term treatment
(14 days).
As we mentioned earlier, the Wnt signalling pathway
converges on GSK-3β. The activation of this pathway leads
to the stabilization and then accumulation of β-catenin and
is involved in gene expression regulation [117]. Lithium was
shown to stabilize β-catenin through inhibition of GSK-3β,
while VPA interacts with the Wnt pathway by increasing β-
catenin transcription.
Among the elements interacting with GSK-3β and
involved in neurogenesis, the family of cAMP response
element binding proteins (CREB) is one of the most widely
investigated. Lithium antagonizes phosphorylated CREB loss
and upregulates both CREB and BDNF in several brain
regions [118]. Moreover, BDNF levels in the rat brain [119–
121]areincreasedaftertreatmentwitheitherlithiumorVPA.
A recent ﬁnding from a gene expression study performed
on cultured rat cortical neurons showed that the treatment
with lithium or VPA induced activation of the promoter
IV of BDNF and that this activation was mediated by the
inhibition of GSK-3 and HDAC, respectively [122]. HDAC
is a key enzyme responsible for the hypoacetylation of
histone proteins, resulting in gene silencing [123, 124], thus
modulating transcription of about 2% of transcribed genes
[125]. As a whole, these data show that VPA can potentially
modulate a large number of long term processes through the
epigenetic regulation of gene expression.
An eﬀect of lithium on BDNF was also shown by
Tseng and coworkers in lymphoblasts from BD patients
responsive to lithium [126]. The authors reported that
lithium treatment in vitro decreased BDNF levels more
signiﬁcantly in BD patients than in controls.
Another key element in neuroprotection is the B-cell
CLL/lymphoma 2 (bcl-2), a protein involved in regulating
cell survival by blocking apoptotic death. It has been shown
that administration of both lithium and VPA induces a
two-fold increase in bcl-2 levels in the frontal cortex of
chronically-treated rodents [127] and in the neuronal cell
lines SH-SY5Y [128].
As discussed in Section 2, newer anticonvulsants, such
as LTG, TPM and GBP, are eﬀective in the maintenance
treatment of BD (LTG) or as add-ons to ﬁrst line mood
stabilizers (TPM, GBP). In contrast to lithium and VPA, less
is known about the mechanism of action of these drugs. A
number of studies have shown that LTG inhibits glutamate
release through sodium and calcium channel blocking [129–
131]. Moreover, LTG signiﬁcantly enhanced the surface
expression of GluR1/2 AMPA receptor in a time- and dose-
dependent manner in cultured hippocampal neurons [132].
LTG was also shown to aﬀect GABA-A receptor-regulated
functions in the CNS. A gene expression study performed
on primary cultured rat hippocampus cells treated with LTG
0.1 mM showed that the expression of the GABA-A receptor
beta3 subunit was increased by the treatment [133]. LTG was
alsoshowntoinhibitGSK-3β inhumanneuroblastomacells,
a mechanism that is shared with VPA and lithium [134].
TPM is an antagonist of the glutamate receptors
KA/AMPA. In addition to this function, TPM was shown
to inhibit glutamate release in epileptic rats [135]. TPM not
only aﬀects glutamate, but also regulates GABA neurotrans-
mission. Several studies have shown that TPM increased
brain GABA levels in healthy humans [136] and enhanced
GABA-stimulated Cl− inﬂux into cerebellar granule neurons
a n dc e r e b r a lc o r t i c a ln e u r o n s[ 137]. Numerous ﬁndings6 Human Genomics and Proteomics
also suggest that, like other mood stabilizers, LTG and
TPM play a key role in neuroprotection. LTG has been
shown to have neuroprotective eﬀects in animal mod-
els of ischemia [138–141] and in the neuronal damage
induced by excitotoxins, mitochondrial toxins and axo-
tomy [142–144]. As regards GBP, the mechanism of its
psychotropic action is still unknown, but some ﬁndings
show that it has neuroprotective eﬀects in ischemic ani-
mal models [145]. Moreover, some evidence suggests that
GBP could negatively regulate glutamate neurotransmission
[146].
3.1. Microarray Gene Expression Studies in Humans. The
ﬁrst report from a genome wide gene expression (GWGE)
study on human derived cell lines was published in 2008
from Seelan and coworkers [147]. In this study, human
neuroblastoma cells were maintained in therapeutic levels
of lithium for 33 days. The transcriptome analysis showed
that a total of 671 genes were diﬀerentially regulated after
lithium treatment. Altered transcripts included genes of
the apoptotic system and the phosphoinositide metabolism.
In another study, Plant and colleagues [148]p e r f o r m e da
transcriptome analysis on human neuroblastoma cells (SH-
SY5Y) treated with either lithium or valproic for 6h or
72h. Findings showed that the treatment with both drugs
determined an altered expression of 936 genes with the
homeodomain protein Six1 being the most signiﬁcantly
upregulated. Moreover, the evaluation of the antiapoptotic
action of lithium and valproate showed that Six1 over-
expression protected the cells from staurosporine-induced
apoptosis via the blockade of caspase-3 activation.
A n o t h e rG W G Es t u d yw a sc a r r i e do u to nm u l t i p l e
prostate human cancer cell lines that were administered
with therapeutic levels of lithium [149]. Lithium signif-
icantly inhibited cell proliferation, which was associated
with reduced DNA replication and S-phase cell cycle arrest.
Moreover, lithium signiﬁcantly decreased the expression of
multiple DNA replication-related genes.
During the 8th Annual Pharmacogenetics in Psychiatry
Meeting [150], Mclnnis reported on a gene expression study
performed on lymphoblasts from BD subjects, incubated
with 1mM lithium chloride for 4, 8 and 16 days. Results
revealed that the chromosome 8 open reading frame 33
(C8orf33) was signiﬁcantly over-expressed after lithium
treatment and that a total of 217 genes was signiﬁcantly
downregulated. C8orf33 activity was found to be associated
with G protein-coupled receptor protein signalling pathway,
neuroactive ligand-receptor interaction, Ca++ signalling
pathway and the regulation of the actin cytoskeleton.
Recently, Sugawara and colleagues [151] evaluated the
eﬀect of both lithium and valproate on gene expression levels
in lymphoblasts derived from three healthy subjects. The
microarray analysis revealed that 44 and 416 genes were
regulated by lithium and valproate, respectively. Among the
18 genes commonly altered, the strongest downregulation
was reported for the vascular endothelial growth factor A
(VEGFA) gene. As for lithium-speciﬁc eﬀects, the most
signiﬁcant altered expressions were reported for the BCL-2
associated X protein (BAX) and the platelet-activating factor
acetylhydrolase isoform 1b, beta subunit (PAFAH1B2).
3.2. Microarray Gene Expression Studies in Rodents. In 2002,
Bosetti and coworkers carried out a GWGE to describe gene
expression changes in brain of rats fed with lithium for
7 (subacute) and 42 (chronic) days respectively using an
array of 4132 genes [152]. Findings showed that lithium
downregulated 25 genes after 7 days but did not upregulate
any gene. In contrast, after 42 days of lithium treatment,
5 0g e n e sw e r eu p r e g u l a t e dw h i l en og e n ew a sd o w n r e g u -
lated. Interestingly, among the downregulated genes was the
inositol polyphosphate-1-phosphatase gene (INPP1), whose
expression was 2.7 times lower after 7 days and 2.6 times
lower after 42 days of lithium treatment.
Another microarray gene expression study was per-
formed by McQuillin and coworkers in 2007 [153]. Find-
ings showed that lithium caused a signiﬁcant change in
the expression level of 121 genes. Among these, lithium
upregulated the period homolog 2 (Per2), the secretogranin
II (Scg2), the BDNF and the IMPA1 genes. Other interesting
ﬁndings consisted of the upregulation mediated by lithium
of the deiodinase (DIO2) and thyroid hormone receptor
interactor 12 (TRIP12) genes, encoding for elements that
might be involved in the development of hypothyroidism, a
long-term side eﬀect caused by lithium treatment in clinical
settings.
Another study by Chetcuti et al. [154] identiﬁed a
signiﬁcantly-diﬀerential expression of a number of genes in
brains of mice treated with lithium for 7 days as compared
to a control sample. Validation by quantitative PCR showed
t h a tﬁ v eg e n e sw e r ed i ﬀerentially expressed after lithium
treatment.Theseincludedgenesinvolvedinmetalionhome-
ostasis and chemical/electrical gradients across membranes,
and regulating RNA polymerase II, protein degradation and
G-protein-coupled signal transduction.
As regards to VPA, a recent study examined gene expres-
sion levels in rat cortical neurons treated with VPA using
microarray technology and reported that 726 genes were
upregulated while 577 were downregulated by the treatment.
Interestingly, the expression of BDNF was upregulated by
VPA while the expression of the α4 subunit of the GABA-A
receptor gene (GABA-ARα4) and the K+/Cl− cotransporter
(KCC2), which are both involved in the development of
GABAergic inhibitory neurons, were downregulated [155].
3.3. MicroRNAs Studies on Lithium Mechanism of Action.
MicroRNAs (miRNA) are a class of endogenous post-
transcriptional regulators binding to complementary seq-
uences in the 3  U T Ro fm u l t i p l et a r g e tm R N A s .T h e
miRNA database (miRBase: http://www.mirbase.org/)c u r -
rently include more than 10000 entries but this number
will presumably increase rapidly in the coming years. A
single miRNA can regulate the expression of a large number
of genes, usually resulting in their silencing. Among their
functions, miRNAs have been shown to regulate neurite
outgrowth, neurogenesis and synaptic plasticity, mainly
through the regulation of mediators such as CREB, methylHuman Genomics and Proteomics 7
CpG binding protein 2 (MECP2), the fragile X mental
retardation 1 protein (FMRP) and elements of the Wnt
pathway [156].
A recent study explored the role of miRNAs in the
mechanism of action of lithium in a sample of lymphoblasts
from BD patients [157]. Each cell line was divided into
two lines: one line was treated with lithium 1mM for 4,
8 and 16 days while the other was grown in lithium-free
medium. Results showed that lithium treatment determined
expression changes in 7 miRNAs after 4 days treatment and
that 4 out of these 7 were signiﬁcantly regulated after 16
days. The most intriguing ﬁnding was reported for miR-
221 and miR-34a, two miRNAs previously shown to be
regulated by lithium and VPA in rat hippocampus [158].
These miRNAs are respectively responsible for regulating
the expression of 29 and 10 genes, including some genes
previously shown to be implicated in BD. Interestingly,
the study by Zhou and colleagues also showed that in
primary culture of hippocampal neurons treated with
lithium or VPA, levels of the protein glutamate receptor
metabotropic 7 (GRM7), one of the miR-34a targets, was
increased thus showing that miR-34a might contribute
to mediating the eﬀe c to fl i t h i u ma n dV P Ao nG R M 7
[158].
4. Pharmacogenomics of Mood Stabilizers
4.1. Linkage Studies on Lithium Response. As a result of its
eﬃcacy and wide clinical use, pharmacogenomic studies on
BD have for the most part focused on response to lithium
prophylaxis. Early linkage studies used pharmacogenomic
approaches based on lithium response as a strategy for
reducing heterogeneity in BD. In 1999, Ewald and colleagues
carried out a haplotype sharing analysis on chromosome 18
in a sample of eight lithium responding BD subjects from
the Faroe Islands who had common ancestors [159]. The
study reported increased haplotype sharing on the distal
part of chromosome 18 (region 18q23). In 1999, Turecki
and coworkers reported a modest linkage with markers in
the chromosome region 18q22.3 in unilateral families of BD
patients responsive to lithium [160]. Interestingly, the same
region was previously shown to be associated with bipolar
in a sample of narrowly deﬁned BDI patients for which,
however, the response to mood stabilizing treatment was not
evaluated [161].
Another linkage study on BD probands for which
response to lithium treatment was considered as inclusion
criteria, [162] reported signiﬁcant LOD scores for the region
of chromosome 12q23-q24 in a large pedigree from the
homogeneous population from Saguenay-Lac-St-Jean (Que-
bec). More recently, Turecki and colleagues [163]p e r f o r m e d
a genome scan on 31 families of probands with excellent
response to lithium using 378 markers. The most signiﬁcant
linkage was found with markers in chromosome regions
15q14 and 7q11.2. However, when the response phenotype
was considered in the analysis, the 15q14 region appeared to
be more probably involved in BD phenotype and 7q11.2 in
lithium response.
4.2. Candidate Gene Studies on Lithium Response. As shown
by the large amount of evidence on the key role of the
inositol pathway in the mechanism of action of lithium,
numerous candidate gene studies on lithium response have
been performed on inositol-related genes. However, while
some authors reported intriguing ﬁndings, a strong evidence
of high impact genes is still lacking.
The gene encoding for phospholipase cγ1( P L C G 1 ) ,a
key enzyme involved in G protein mediated signals and
in the inositol pathway, has been investigated in several
studies. One paper reported association for a dinucleotide
repeat in PLCG1 in a sample of 136 BD patients excellent
responders to lithium and 163 controls [167]. The same
study reported a modest linkage with this polymorphism
in a sample of unilineal families. However, these ﬁndings
were not replicated in a re-examination study performed
in a sample of Norwegian lithium-treated bipolar patients
sub-classiedaslithiumresponders,nonresponders,orpartial
responders/unclassied[174].PLCG1wasfurtherinvestigated
in the study by Ftouhi-Paquin and coworkers [175], in which
theauthorsscreenedthegeneforfunctionalpolymorphisms.
While three single nucleotide polymorphism (SNPs) in the
translated region of PLCG1 were identiﬁed, none of the
markers was found to be associated with BD in a sample of
133 excellent responders to lithium and 99 healthy controls.
Other genes encoding for elements of the inositol
pathway have been tested for association with lithium
response. The INPP1 was ﬁrst investigated by Steen and
coworkers in 1998 [166]. The authors showed association
for the silent variant C937A and response to lithium in a
Norwegian sample of 23 BD patients and 20 controls but
not in a sample of 54 BD and 50 controls from Israel.
Nevertheless, a recent study failed to conﬁrm the association
for this polymorphism and lithium response in a sample
of 134 BD patients comprised of 61 full responders, 49
nonresponders and 24 partial responders to lithium [186].
Positive association with lithium response was also shown
for two polymorphisms in the gene encoding the inositol
monophosphatase 2 (IMPA2) in the study by Dimitrova and
colleagues[183].However,therelativelysmallsizeandpower
of the BD sample characterized for lithium response did not
allow the authors to draw deﬁnitive conclusions.
The gene encoding for the IMPA1 has been studied in
two papers reporting no association with lithium response
[56, 165]. Several studies have investigated for association
another gene encoding for a key element in lithium mech-
anism of action: the GSK-3β gene [56, 184–186]. However,
among the four studies performed so far, only Benedetti
and coworkers reported association between the −50 T/C
polymorphism and lithium response, thus providing no
conclusive results [184].
Another set of interesting ﬁndings was produced for
the BDNF gene. In 2005, Rybakowski and colleagues
[181] reported positive association between SNP rs6265
(Val66Met) and better response to lithium in a sample of
88 BD patients. The Val66Met is a functional polymorphism
with the Met allele shown to be associated with lower
depolarization-induced secretion of the protein in neurons
[195]. The Val/66Met polymorphism was investigated by8 Human Genomics and Proteomics
Table 1: Pharmacogenetic studies in lithium response.
Gene Sample Association Reference
TH 54 BD lithium responders and 94 controls No association [164]
IMPA1 21 BD patients: 7R, 7NR, 7UN No association [165]
INPP1
Norwegian sample: 23 BD patients (9R,
9NR, 5PR/UN) and 20 controls
Association between the silent variant
C937A and response to lithium in the
Norwegian but not in the Israeli sample
[166]
Israeli sample: 54 BD patients (16R,
15NR, 23PR/UN) and 50 controls
PLCG1 136 BD lithium responders and 163
controls
Association for PLCG1 (CA)n repeat
alleles
[167]
DRD3 43 BD + 12 MD patients characterized
for lithium response No Association [168]
TPH 90 BD + 18 MD patients characterized
for lithium response





100 BD + 25 MD patients characterized
for lithium response No association [170]
MAO-A 138 BDI lithium responders and 108
Controls No association [171]
5-HT1A, 5-HT2A,
5-HT2C 102 BD +22 MD patients No association [172]
GABRA3, GABRA5,
GABRB3
138 BDI lithium responders and 108
controls No association [173]
PLCG1 61 BD patients: 29R, 16NR, 16PR/UN No association [174]
PLCG1 133 BD lithium responders and 99
controls No association [175]
5-HTT 167 BD + 34 MD patients characterized
for lithium response
Association between 5-HTTLPR s/s and
worse response
[176]
COMT, MAO-A, Gβ3 160 BD + 41 MD patients characterized
for lithium response No association [177]
5-HTT 83 BD patients: 36 R, 47NR Association between 5-HTTLPR l/s and
better response
[178]
5-HTT 67 BD patients: 18 ER, 35 PR, 14 NR Association between 5-HTTLPR s/s and s
and worse response
[179]
XBP1 56 BD patients: 10R, 24PR, 22NR Association between x116C/C and
x116C/G genotypes and worse response
[180]
BDNF 88 BD patients characterized for response
to lithium
Association between rs6265 Val\Met and
better response
[181]
5-HTR2A, 5-HTR2C 92 BD patients: 24 ER, 48 PR, 20 NR No association [182]
IMPA2
237 parents-oﬀspring trios and in 174
cases and 170 controls ascertained for
lithium response
Association between rs3786282 and
599+97G/A and good response to lithium
in a subsample of the trios sample
[183]
GSK3B 88 BDI patients characterized for lithium
response
Association between the C allele of
−50T/C and better response to lithium
[184]









184 BD patients: 92 R, 92 NR
Association between SNPs rs1387923 and
rs133845 in the NTRK2 gene and lithium
response in BD patients with suicidal
ideation as well as in BD patients with
posttraumatic stress disorder
[56]
BDNF, 5-HTT 121 BD patients: 31 ER, 54 PR, 26 NR
Positive interactive eﬀect between 5-
HTTLPR s/s and l/swith BDNF rs6265
Val/Val in NR
[187]Human Genomics and Proteomics 9
Table 1: Continued.
Gene Sample Association Reference
BDNF, NTRK2 108 BD patients: 25 ER, 55 PR, 28 NR Association between BDNF rs988748 and




249 BD patients: 180R, 69NR and 127
controls
Association between CREB1-1H and 7H
SNPs and better response
[189]
DRD1 92 BD patients: 24 ER, 48 PR, 20 NR Association between allele G of −48 A/G
and worst response
[190]
FYN 101 BD patients: 24 ER, 51P R, 26 NR Trend for association between the T allele
of rs3730353 and worse response
[191]
DGKH
197 Sardinian BD I patients 91 of which
characterized for lithium response (24
FR, 67 PR + NR) and 300 controls
No association [22]
NR1D1, DGKH 199 BD patients: 57 FR, 142 PR + NR No association [192]




155 BD patients: 43 R, 112 PR + NR No association [194]
TH: tyrosine hydroxylase; INPP1: inositol polyphosphate-1-phosphatase; IMPA1: inositol(myo)-1(or 4)-monophosphatase 1; PLCG1: phospholipase
C, gamma 1; TPH: tryptophan hydroxylase; DRD1: dopamine receptor D1; DRD4: dopamine receptor D4; GABRA1: gamma-aminobutyric acid A
receptor, alfa 1; MAO-A: monoamine oxidase A; 5-HTR1A: 5-hydroxytryptamine receptor 1A; 5-HTR2A: 5-hydroxytryptamine receptor 2A; 5-HTR2C: 5-
hydroxytryptamine receptor 2C; GABRA3: gamma-aminobutyric acid A receptor, alfa 3; GABRA5: gamma-aminobutyric acid A receptor, alfa 5; GABRB3:
gamma-aminobutyric acid A receptor, beta 3; 5-HTT: solute carrier family 6 member 4 (serotonin transporter); 5-HTTLPR: serotonin-transporter-linked
promoter region; FYN: Src-family tyrosine kinases; COMT: catechol-O-methyl transferase; Gβ3: G protein beta 3; XBP1: X-box binding protein 1; BDNF:
brain derived neurotrophic factor; IMPA2: inositol(myo)-1(or 4)-monophosphatase 2; GSK3B: glycogen synthase kinase 3 beta; AP2-B: activating enhancer-
binding protein 2 beta 3; GRK3: beta-adrenergic receptor kinase 2 (BARK2); NTRK2: neurotrophic tyrosine kinase, receptor, type 2; MARKS: myristoylated
alanine-rich C-kinase substrate; CREB1: cAMP responsive element binding protein 1; CREB2: cAMP responsive element binding protein 2; CREB3: cAMP
responsive element binding protein 3; FYN: Src-family tyrosine kinases; DGKH: diacylglycerol kinase, eta; NR1D1: nuclear receptor subfamily 1, group D,
member 1; PDLIM5: PDZ and LIM domain 5; BD: bipolar disorder; MD: major depression; R: responders; FR: full responders; PR: poor responders; NR: non
responders; ER: excellent responders; UN: unclassiﬁed.
Rybakowski and coworkers in a further study reporting
an interactive eﬀect between the Val/Val genotype and the
s/s and l/s genotypes of the serotonin-transporter-linked
promoter region (5-HTTLPR) polymorphism in a sample of
107 BD subjects characterized for lithium response [196].
Other association studies of 5-HTTLPR polymorphism in
lithium response are discussed hereafter in this review.
Another study by the same group recently investigated
for association four SNPs in the BDNF gene and three SNPs
in the gene encoding for the neurotrophic tyrosine kinase,
receptor, type 2 (NTRK2) in a sample of 108 BD patients.
Findings showed association between the BDNF Val66Met
polymorphism and degree of response to lithium, but no
association was reported for NTRK2 polymorphisms [188].
The same gene was also investigated in the paper by Bremer
et al. [56] in which signiﬁcant association between lithium
response and two SNPs within NTRK2 was shown in BD
patients with suicidal ideation as well as in BD patients
with posttraumatic stress disorder. Interestingly, in 2009
Szczepankiewicz and coworkers [191] have investigated the
association between the Src-family tyrosine kinases (FYN)
gene and lithium response in a sample of 101 BD patients
characterized for lithium response. FYN is a member of
the protein-tyrosine kinase oncogene family and belongs to
the protein kinase family phosphorylating NMDA receptor
subunits, participating in the regulation of ion transmission
and BDNF/TrkB signal transduction pathway. In this study
the authors reported a trend for association for one of the
polymorphisms with a worse response to lithium. While the
study does not strongly support the involvement of this gene
in lithium response, ﬁndings are intriguing in the light of a
previous paper by the same group in which an association
for FYN polymorphisms and BD was reported [197]. As
a whole, these results corroborate the evidence indicating
a key role of the BDNF/Trk signaling pathway in lithium
response and BD.
Another interesting ﬁnding was reported in the paper by
Mamdani and coworkers, in which the authors investigated
the association between CREB1, CREB2 and CREB3 genes
and response to lithium in a sample comprised of 180 BD
lithium responders, 69 non responders and 127 controls
[189]. Findings showed association between CREB1-1H and
7H SNPs and response to lithium.
As we mentioned earlier, several authors showed that the
DGKH gene was associated with BD. Squassina et al. [22]
recently investigated the three SNPs previously found to be
associated with BD by Baum et al. [12], in a sample of 197
Sardinian BD I patients, 91 of whom were characterized for
lithium response. While the authors failed to replicate the
associationforindividualSNPs,asigniﬁcantassociationwith
BD was reported for a haplotype of the three SNPs. However,
the study did not show statistically signiﬁcant association10 Human Genomics and Proteomics
with response to lithium. Moreover, this lack of association
has been conﬁrmed in an extended cohort of Sardinian BD
patients charachterized for lithium treatment [198].
Along with inositol pathway genes, a number of papers
have also dealt with genes encoding for elements of neu-
rotransmitters’ systems. The 5-HTTLPR polymorphism has
been investigated in lithium response by a number of
authors. Three studies reported association between the
short allele (s) and/or genotypes carrying the s allele and a
worse response to lithium [176, 178, 179]. Another study
investigated the interactive eﬀect of 5-HTTLPR and BDNF
Val66Met in a sample comprised of 31 patients classied
as excellent responders, 54 as partial responders and 26
as nonresponders to lithium prophylaxis [187]. Findings
showed that patients with 5-HTTLPR s/s and l/s genotypes
having the BDNF Val/Val genotype were more frequent in
non responders than in the other groups.
While to date the association with 5-HTTLPR has
been replicated most frequently in lithium response studies,
other authors failed to report positive ﬁndings for this
polymorphism [186, 194].
Another interesting ﬁnding for serotonin-related genes
was reported in a paper by Serretti et al. [169]i nw h i c h
the authors identiﬁed an association between variants in the
TPH gene and worse response to lithium in a sample of 90
BD and 18 major depressive patients.
A number of studies have also dealt with dopamine
system genes, but to date only one paper showed positive
association. Rybakowski and coworkers reported an associ-
ation between the G allele and G/G genotype of the −48
A/G polymorphism in the DRD1 gene and worse response
to lithium [190]. A detailed list of pharmacogenetic studies
in lithium response can be found in Table 1.
4.3. Genome Wide Association Studies on Lithium Response.
To date only one GWAS has been published reporting
ﬁndings on a sample of bipolar patients characterized for
lithium response [202]. The results showed that a SNP
in the glutamate receptor ionotropic, AMPA 2 (GLUR2)
gene was associated with time to recurrence. However, the
association did not reach the genome wide signiﬁcance and
the characterization of lithium response of the replication
sample was performed using a diﬀerent methodology.
Some international joint eﬀorts are being undertaken
to identify the genetic variants involved in the modulation
of lithium response. The Consortium on Lithium Genetics
(ConLiGen, www.conligen.org), created in 2008, has already
collected a sample of 1,500 BD patients retrospectively
assessed using narrow criteria for the phenotypic charac-
terization of treatment response [203]. The GWAS analysis
is currently ongoing, and new genetic ﬁndings on lithium
response and related ADRs will soon be available to the
scientiﬁc community.
4.4. Gene Expression Studies on Lithium Response. Only
a small number of gene expression studies have been
performed thus far using human tissues from patients
characterized for the response to lithium. In 2004, Sun and
coworkers [204] published ﬁndings from a microarray gene
expression studyon lymphoblasts fromBDpatients excellent
responders to lithium. After chronic lithium treatment in-
vitro, the authors found that the expression levels were
altered for 7 genes, 5 of which were conﬁrmed by Northern
blotting analysis. These 5 genes codiﬁed for elements of
pathways involved in neurotransmission and in processes
that might be related to the lithium mechanism of action,
such as the alpha I B-adrenoceptor (αIB-AR), acetylcholine
receptor protein alpha chain precursor (ACHR) and cAMP-
dependent 3 ,5  -cyclic phosphodiesterase 4D (PDE4D).
A recent study measured the expression levels of the gene
codifying for the PDZ and LIM domain 5 (PDLIM5) protein
inasampleofBDpatientscharacterizedforlithiumresponse
and a sample of controls [193]. PDLIM5 is an adaptor
protein that selectively binds the protein kinase C epsilon
(PKCε)toitstarget,theN-typeCa2+channels,voltage-gated
Ca2+channelsspecicallyexpressedinaxons[205].Thestudy
failed to show signiﬁcant diﬀerences in expression levels
between lithium responders and partial/non responders or
controls.
4.5. Pharmacogenomic Studies on other Mood Stabilizers.
Compared with lithium, much less evidence is available on
thepharmacogenomicsofothermoodstabilizingtreatments.
A recent study investigated the association between the -
116C/G polymorphism in the X-box binding protein 1
(XBP1) gene and reponse to VPA in a sample of 51 bipolar
patients [198]. XBP1 is a an endoplasmic reticulum (ER)
stress-responsive transcription factor regulating major histo-
compatibility complex (MHC) class II genes by binding to a
promoter [206]. The study showed an association between
the G allele (that is associated with reduced transcription
activity of XBP1) and a better response to VPA as compared
to the C allele. The XBP1 gene was also shown to be involved
in the pathophogenesis of BD [207], thus supporting the
notion that its product might play a role in both the disease
and the reponse to mood stabilizers.
Another candidate gene study examined the role of
the Val158Met polymorphism in the catechol-O-methyl
transferase (COMT) gene in response to mood stabilizers in
a sample of 144 BDI patients and 157 controls [201]. During
the treatment period, all patients were under mood stabilizer
therapy with either lithium, VPA or CBZ. The results
showed that the Met/Met genotype was more frequent in
nonresponders than in responders, while no diﬀerences were
detected between BD patients and controls. However, since
the sample was not sub-divided according to the diﬀerent
t y p e so ft r e a t m e n t ,i ti sn o tp o s s i b l et od r a wc o n c l u s i o n so n
the role of COMT Val66Met in the response to speciﬁc mood
stabilizers.
To our knowledge, only one pharmacogenetic study
based on response to LTG has been performed. More
precisely, Perlis and coworkers examinated the association
between 19 SNPs located in several genes and response
to Olanzapine/Fluoxetine combination (OFC) or LTG in
a sample of 88 OFC-treated and 85 LTG treated bipolar
I depression patients [200]. In regard to LTG treatment,Human Genomics and Proteomics 11
Table 2: Pharmacogenetic studies in response to other mood stabilizing medications.
Gene Sample Association Reference
COMT 42 BD patients characterized for response
to olanzapine






173 bipolar I depression patients: 88
OFC-treated and 85 LTG treated
Association between DRD2, DBH, HRH1, MCR2,
NR3C1 and response to LTG [200]
Association between DRD3, HRH1 and response to
OFC
XBP1 51 BD patients characterized for response
to VPA
Association between the G allele of −116C/G and better
response [198]
COMT
144 BD patients characterized for
response to mood stabilizers (Li, VPA,
CBZ)
Association between the Val158Met Met/Met and non
response to mood stabilizers [201]
COMT: catechol-O-methyl transferase; DRD2: dopamine receptor D2; DRD3: dopamine receptor D3; DRD4: dopamine receptor D4; DBH: dopamine beta-
hydroxylase; HRH1: histamine H1 receptor; ANKK1: ankyrin repeat and kinase domain containing 1; MCR2: melanocortin 2 receptor; NR3C1: nuclear
receptor subfamily 3, group C, member; XBP1: X-box binding protein 1; BD: bipolar disorder; OFC: Olanzapine/Fluoxetine combination; LTG: lamotrigine;
VPA: valproate; CBZ: carbamazepine.
ﬁndings showed that SNPs within the dopamine D2 receptor
(DRD2), dopamine β-hydroxylase (DBH), glucocorticoid
receptor (NR3C1), histamine H1 receptor (HRH1) and
melanocortin 2 receptor (MCR2) genes were associated with
the treatment response. Table 2 lists most of the association
s t u d i e sc a r r i e do u tt od a t ei nr e s p o n s et oo t h e rm o o d
stabilizing medications.
4.6. Pharmacogenomic of Antipsychotics in Bipolar Disorder.
Despite the constant increase in the use of atypical antipsy-
chotics in the maintenance treatment of BD, still very few
studies have investigated the genetic underpinnings of their
therapeutic response. In 2006, D´ avila et al. [199]i n v e s t i ga t e d
the role of COMT Val158Met polymorphism on psychotic
features in 42 BDI patients, further testing the hypothesis
of a possible inﬂuence of this variant on blood plasma
concentrationofmetabolitesofdopamineandnoradrenaline
and on the severity of the disorder and the response to
olanzapine and lithium. No signiﬁcant ﬁndings emerged
with regard to treatment response to olanzapine as well as
for the other markers tested. Aiming to evaluate common
genetic variation for association with clinical improvement
in BDI depression following treatment with OFC, Perlis et
al. [200] analyzed a cohort of 88 patients treated with OFC,
showing signiﬁcant association for dopamine D3 receptor
(DRD3) and HRH1 genes and response to OFC. The dearth
of pharmacogenomic studies on antipsychotics in BD should
encourage research eﬀorts aiming to identify possible genetic
predictors of response, especially in light of the ever-wider
use of these agents as maintenance treatments.
5.SummaryandFuturePerspectives
Pharmacogenomic approaches in BD have thus far con-
centrated on identifying genetic predictors of treatment
responsetomoodstabilizers.However,basedontheevidence
that lithium responsive BD patients share common clinical
features, pharmacogenomics has also been used as strategy
for enucleating subgroups of individuals characterized by
lower phenotypic and presumably genetic heterogeneity,
thus also possibly increasing the power of detecting causative
variants of BD. While linkage studies performed on BD
patients responsive to lithium have highlighted some chro-
mosomal regions (7q11.2, 15q14, 18q23), further studies
have reported no association for speciﬁc genes within these
regions. Candidate-gene approaches have so far focused on
genes codifying for elements of biological pathways shown
to be target of lithium, such as proteins of the intracellular
second messenger cascade mediated by inositol, Wnt and
neurotrophins pathways and the GSK-3β protein. Along
with ﬁndings from gene expression studies, these data have
provided intriguing, although yet inconclusive, insights into
the understanding of the genetic underpinnings of lithium
response.
As regards to the anticonvulsant VPA, the small number
of pharmacogenetic studies performed so far failed to
provide evidence for high impact genes. However, the
associations reported for XBP1 and COMT genes are still
intriguing in light of their key role in the mechanism
of action of VPA and in pathways putatively involved in
modulating the pathophysiology of BD. As for LTG, evidence
for association with treatment response has thus far been
reported for DRD2, β-hydroxylase, glucocorticoid receptor,
HRH1 and melanocortin 2 genes. While these ﬁndings come
from the only candidate gene study performed to date, they
shed light on genes encoding for elements shown to be
involved in both the LTG mechanism of action and BD.
Overall, genetic data on response to mood stabilizers
are informative tools that along with data on phenotypic
and environmental factors might be useful in predicting
individual treatment response proﬁles thus paving the way
to targeted therapies.
To facilitate the implementation process from pharma-
cogenomics to personalized medicine in the long-term treat-
ment of BD, various research areas still need to be developed.
For instance, ﬁndings are still substantially lacking as
regards safety pharmacogenomics, an approach dedicated12 Human Genomics and Proteomics
to avoiding ADRs [208]. Phenotypically, an ADR from a
drug is generally assessed more objectively. Such events
usually occur a short time after the patient experiences the
drug, so the precise phenotypic response can be speciﬁ-
cally, sensitively and accurately documented [208]. Since
it could accurately deﬁne individuals who might be at
higher personal risk of an adverse event, safety pharmacoge-
nomics acquires particular importance in mood stabilizing
treatments in BD, given their long-term nature and their
speciﬁc pharmacokinetic/pharmacodynamic properties. For
instance, lithium is characterized by a narrow therapeutic
index, and its clinical management is greatly impacted by
important side eﬀects, above all the alteration of thyroid
function and nephrogenic diabetes insipidus. Moreover,
the other available therapeutic tools, anticonvulsants and
antipsychotics, also present a wide range of side eﬀects
ranging from allergic reaction to haematological toxicity
and weight gain. In clinical practice, these side eﬀects
can dramatically aﬀect the positive outcomes of long-term
treatments, since patients having a high degree of response
may be forced to stop eﬀective maintenance treatments due
to the onset of serious ADRs.
In conclusion, once pharmacogenomics produces clear
data to reliably determine the extent of the genetic con-
tribution to the treatment response phenotype and the
predictive power of positive response outcome associated
with them, the personalized therapy strategy can be quite
easily integrated into clinical settings ultimately leading to
the selection of drugs that will be both safe and eﬀective for
a patient.
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